Comparative Pharmacology
Head-to-head clinical analysis: OGEN 5 versus STILBETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 5 versus STILBETIN.
OGEN 5 vs STILBETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
Diethylstilbestrol (STILBETIN) is a nonsteroidal estrogen that binds to estrogen receptors, activating estrogen-responsive genes, leading to increased synthesis of proteins involved in growth and differentiation of female reproductive tissues.
0.625 mg orally once daily, adjusted based on response.
25 mg orally 3 times daily for 5 days; repeat if necessary after 1 month.
None Documented
None Documented
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Terminal elimination half-life is approximately 1-2 hours (range 1-3 h) for estradiol; clinical relevance: requires multiple daily dosing (e.g., 3-4 times/day) for sustained effect.
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Primarily renal as glucuronide and sulfate conjugates; approximately 50-80% of a parenteral dose excreted in urine within 24 hours; 10-20% via bile into feces.
Category C
Category C
Estrogen
Estrogen